Wei Zou

8.8k total citations · 3 hit papers
60 papers, 3.6k citations indexed

About

Wei Zou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Wei Zou has authored 60 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Wei Zou's work include Cancer Immunotherapy and Biomarkers (27 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Genomics and Diagnostics (13 papers). Wei Zou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Genomics and Diagnostics (13 papers). Wei Zou collaborates with scholars based in United States, China and France. Wei Zou's co-authors include Marcin Kowanetz, Marcus Ballinger, Achim Rittmeyer, Alan Sandler, Daniel Waterkamp, Alexander I. Spira, Louis Fehrenbacher, Daniel S. Chen, Á. Artal and Jing Yi and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Wei Zou

50 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2016 2.1k citations Alexander I. Spira, Marcus Ballinger et al. profile →
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

2016 409 citations Wei Zou, Priti S. Hegde et al. Journal of Clinical Oncology profile →
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

2021 316 citations Mark A. Socinski, Makoto Nishio et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wei Zou United States	18	3.1k	2.0k	831	683	408	60	3.6k
Davey B. Daniel United States	19	2.2k 0.7×	2.1k 1.0×	362 0.4×	688 1.0×	538 1.3×	82	3.3k
Achim Rittmeyer United States	26	4.9k 1.6×	3.5k 1.8×	1.1k 1.3×	687 1.0×	593 1.5×	91	5.7k
Alexander I. Spira United States	10	2.2k 0.7×	1.3k 0.7×	636 0.8×	384 0.6×	228 0.6×	19	2.5k
William J. Geese United States	20	2.5k 0.8×	1.4k 0.7×	619 0.7×	455 0.7×	481 1.2×	43	3.0k
Hira Rizvi United States	23	2.9k 0.9×	1.7k 0.8×	508 0.6×	426 0.6×	683 1.7×	64	3.5k
Mitsuhiro Takenoyama Japan	36	2.2k 0.7×	1.9k 0.9×	1.1k 1.3×	374 0.5×	965 2.4×	221	3.9k
Asim Amin United States	27	2.6k 0.9×	1.1k 0.5×	1.1k 1.3×	431 0.6×	905 2.2×	73	3.4k
Roxana Dronca United States	33	2.8k 0.9×	771 0.4×	1.4k 1.6×	290 0.4×	1.0k 2.5×	109	3.8k
Jifang Gong China	29	1.7k 0.6×	928 0.5×	381 0.5×	603 0.9×	785 1.9×	147	2.9k
Alfonso Gúrpide Spain	23	1.5k 0.5×	1.0k 0.5×	782 0.9×	392 0.6×	511 1.3×	75	2.5k

Countries citing papers authored by Wei Zou

Since Specialization

Citations

This map shows the geographic impact of Wei Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Zou more than expected).

Fields of papers citing papers by Wei Zou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Zou. The network helps show where Wei Zou may publish in the future.

Co-authorship network of co-authors of Wei Zou

This figure shows the co-authorship network connecting the top 25 collaborators of Wei Zou. A scholar is included among the top collaborators of Wei Zou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei Zou. Wei Zou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zou, Wei, Chang Liu, Han Wang, et al.. (2025). TPS genes expression pattern and terpenoids content in the leaves and flowers of Chimonanthus praecox and C. salicifolius. Scientific Reports. 15(1). 19474–19474.

Powles, Tom, Ariel Galapo Kann, M. Gross Goupil, et al.. (2025). LBA8 IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. Annals of Oncology. 36. S1634–S1634.

Ding, Yiqing, et al.. (2024). Functional Divergence of the Closely Related Genes PhARF5 and PhARF19a in Petunia hybrida Flower Formation and Hormone Signaling. International Journal of Molecular Sciences. 25(22). 12249–12249.

Zou, Wei, Vinzent Rolny, Martin Reck, et al.. (2023). Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150. Tumor Biology. 46(s1). S177–S190. 2 indexed citations

Pellini, Bruna, Russell W. Madison, Ole Gjoerup, et al.. (2023). Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(22). 4596–4605. 25 indexed citations

Bruno, René, Mathilde Marchand, Kenta Yoshida, et al.. (2023). Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical Cancer Research. 29(6). 1047–1055. 13 indexed citations

Zou, Wei, Xin Luo, Mengyuan Gao, et al.. (2023). Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function. British Journal of Pharmacology. 181(2). 257–272. 7 indexed citations

Assaf, Zoe J., Wei Zou, Alexander D. Fine, et al.. (2023). A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nature Medicine. 29(4). 859–868. 75 indexed citations

Wan, Qianqian, et al.. (2023). Genome-wide identification and analysis of the evolution and expression pattern of the SBP gene family in two Chimonanthus species. Molecular Biology Reports. 50(11). 9107–9119.

10.

Nomburg, Jason, Wei Zou, Shobha Vasudevan, et al.. (2022). Long-read sequencing reveals complex patterns of wraparound transcription in polyomaviruses. PLoS Pathogens. 18(4). e1010401–e1010401. 9 indexed citations

11.

Zou, Wei, Min Xiong, Siyuan Hao, et al.. (2021). The SARS-CoV-2 Transcriptome and the Dynamics of the S Gene Furin Cleavage Site in Primary Human Airway Epithelia. mBio. 12(3). 7 indexed citations

12.

Patil, Namrata S., Wei Zou, Simonetta Mocci, et al.. (2021). C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. PLoS ONE. 16(2). e0246486–e0246486. 7 indexed citations

13.

Assaf, Zoe J., Alexander D. Fine, Wei Zou, et al.. (2021). MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150. Journal of Thoracic Oncology. 16(10). S905–S906. 2 indexed citations

14.

Zou, Wei, Stephanie J. Yaung, Marcus Ballinger, et al.. (2021). ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy. JCO Precision Oncology. 5(5). 827–838. 35 indexed citations

15.

Li, Zhen, Ji Zhang, Wei Zou, et al.. (2021). The methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism is associated with breast cancer subtype susceptibility in southwestern China. PLoS ONE. 16(7). e0254267–e0254267. 6 indexed citations

16.

Gadgeel, Shirish M., Fred R. Hirsch, Keith M. Kerr, et al.. (2021). Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical Lung Cancer. 23(1). 21–33. 13 indexed citations

17.

Li, Zhen, Wei Zou, Ji Zhang, et al.. (2020). Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. Frontiers in Pharmacology. 11. 580251–580251. 55 indexed citations

18.

Yaung, Stephanie J., Fergal Casey, Maureen Peterson, et al.. (2019). Evaluation of clonal hematopoiesis in late stage NSCLC using a next-generation sequencing panel targeting cancer genes.. Journal of Clinical Oncology. 37(15_suppl). 9050–9050. 1 indexed citations

19.

Patil, Namrata S., Luisella Righi, Hartmut Koeppen, et al.. (2017). Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(1). 124–133. 43 indexed citations

20.

Kowanetz, Marcin, Wei Zou, David S. Shames, et al.. (2016). Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Annals of Oncology. 27. vi23–vi23. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact